Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161610 | 0.84 | NOTUM (0.33) | P2RX7MAPK1 | |
| SCHEMBL31161377 | 0.84 | P2RX7 (0.33) | P2RX7MAPK1 | |
| SCHEMBL13241467 | 0.83 | P2RX7 (0.30) | P2RX7 | |
| SCHEMBL31161318 | 0.80 | EGFR (0.32) | P2RX7 | |
| SCHEMBL24651155 | 0.77 | NOTUM (0.36) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL31161182 | 0.76 | NOTUM (0.34) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL15956758 | 0.76 | NOTUM (0.34) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL30292339 | 0.73 | ALDH1A1 (0.33) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL24651189 | 0.71 | NOTUM (0.50) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL1405509 | 0.69 | NOTUM (0.36) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | LPL 4213/4885LIPG 4692/4885P2RX7 3438/4885 |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIK3CA, PIP5K1B, PIK3CD | LPL 3810/4885LIPG 2416/4885P2RX7 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.